Walgreens Boots Alliance has sold more shares of drug distributor Cencora for proceeds of about $300 million, “primarily for debt paydown and general corporate purposes,” the company said ...

Cencora (NYSE:COR) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding ...

Cencora (COR) has significantly expanded the number and type of medications available in its sure supply program, a drug shortage mitigation initiative designed to provide health systems with ...

Over the past year, many Cencora, Inc. ( NYSE:COR ) insiders sold a significant stake in the company which may have... CONSHOHOCKEN, Pa., February 07, 2025--Cencora, Inc. (NYSE: COR) today ...

Investors might want to bet on Cencora (COR), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

Baird raised the firm’s price target on Cencora (COR) to $307 from $305 and keeps an Outperform rating on the shares. The firm noted it was another beat and raise quarter. Published first on ...

Shares of Cencora (COR) have been strong performers lately, with the stock up 13.4% over the past month. The stock hit a new 52-week high of $256.81 in the previous session. Cencora has gained 13. ...

Hello and welcome everyone to the Cencora Q1 fiscal year 2025 earnings call. My name is Becky and I’ll be your Operator today. During the presentation, you can register a question by pressing ...

Cencora, Inc. (COR), headquartered in Pennsylvania, is a global pharmaceutical sourcing and distribution leader offering innovative healthcare solutions and services. With a market cap of $45.2 ...

Cencora, Inc. is a pharmaceutical sourcing and distribution services company. It operates through the United States (U.S.) Healthcare Solutions and International Healthcare Solutions segments.